Scientists have discovered a rare gene in the tumors of some colorectal cancer patients which could lead to more personalized treatments.

A rare gene in the tumors of some colorectal cancer patients could lead to more accurate diagnoses and, eventually, personalized treatments.

This finding could lead to more accurate diagnoses and, eventually, personalized treatments that target the protein expressed by the gene.

The MSK clinical trial was investigating — for the first time ever — if immunotherapy alone could beat rectal cancer.

The oncolytic virus has been shown to shrink colon, lung, breast, ovarian and pancreatic cancer tumors in preclinical laboratory models.